Neurobiology of Aging
Volume 28, Issue 5 , Pages 727-734 , May 2007

Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures

  • Jakob C. Mueller

      Affiliations

    • Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technical University Munich (TUM), Ismaningerstr. 22, 81675 München, Germany
    • Institute of Medical Statistics and Epidemiology, TUM, Germany
    • These two authors contributed equally to this work.
    • ,
  • Matthias Riemenschneider

      Affiliations

    • Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technical University Munich (TUM), Ismaningerstr. 22, 81675 München, Germany
    • These two authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author. Tel.: +49 89 4140 4214; fax: +49 89 4140 4888.
    • ,
  • Andreas Schoepfer-Wendels

      Affiliations

    • Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technical University Munich (TUM), Ismaningerstr. 22, 81675 München, Germany
    • ,
  • Henning Gohlke

      Affiliations

    • Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technical University Munich (TUM), Ismaningerstr. 22, 81675 München, Germany
    • Institute of Genetic Epidemiology, GSF, München-Neuherberg, Germany
    • ,
  • Lidija Konta

      Affiliations

    • Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technical University Munich (TUM), Ismaningerstr. 22, 81675 München, Germany
    • ,
  • Patricia Friedrich

      Affiliations

    • Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technical University Munich (TUM), Ismaningerstr. 22, 81675 München, Germany
    • ,
  • Thomas Illig

      Affiliations

    • Institute of Genetic Epidemiology, GSF, München-Neuherberg, Germany
    • ,
  • Simon M. Laws

      Affiliations

    • Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technical University Munich (TUM), Ismaningerstr. 22, 81675 München, Germany
    • ,
  • Hans Förstl

      Affiliations

    • Department of Psychiatry and Psychotherapy, TUM, Germany
    • ,
  • Alexander Kurz

      Affiliations

    • Department of Psychiatry and Psychotherapy, TUM, Germany

Received 26 January 2006 ,Revised 21 February 2006 ,Accepted 20 March 2006.

References 

  1. Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, et al. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum Genet. 2001;109(6):646–652
  2. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–265
  3. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science. 2000;290:2302–2303
  4. Bian L, Yang JD, Guo TW, Sun Y, Duan SW, Chen WY, et al. Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese. Neurology. 2004;63(2):241–245
  5. Bickeboller H, Campion D, Brice A, Amouvel P, Hannequin D, Didierjean O, et al. Alzheimer's disease: genotype specific risks by age and sex. Am J Hum Genet. 1997;60:439–446
  6. Blacker D, Bertram L, Saunders A, Moscarillo T, Albert M, Wiener H, et al. Results of a high resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet. 2003;12:23–32
  7. Blomqvist ME, Chalmers K, Andreasen N, Bogdanovic N, Wilcock GK, Cairns NJ, et al. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging. 2005;26(6):795–802
  8. Blomqvist ME, Silburn PA, Buchanan DD, Andreasen N, Blennow K, Pedersen NL, et al. Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics. 2004;5(2):115–119
  9. Boussaha M, Hannequin D, Verpillat P, Brice A, Frebourg T, Campion D. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci Lett. 2002;329(1):121–123
  10. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923
  11. Daw E, Payami H, Nemens E, Nochlin D, Bird T, Schellenberg G, et al. The number of trait loci in late-onset Alzheimer's disease. Am J Hum Genet. 2000;66:196–204
  12. Edbauer D, Willem M, Lammich S, Steiner H, Haass C. Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J Biol Chem. 2002;277(16):13389–13393
  13. Edland SD, Wavrant-De Vriese F, Compton D, Smith GE, Ivnik R, Boeve BF, et al. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett. 2003;345(1):21–24
  14. Ertekin-Taner N, Allen M, Fadale D, Scanlin L, Younkin L, Petersen RC, et al. Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat. 2004;23(4):334–342
  15. Ertekin-Taner N, Graff-Radford N, Younkin L, Eckerman C, Baker M, Adamson J, et al. Linkage of plasma Ab42 to a quantitative locus on chromosome 10 in late onset Alzheimer's disease pedigrees. Science. 2000;290:2303–2304
  16. Ertekin-Taner N, Ronald J, Feuk L, Prince J, Tucker M, Younkin L, et al. Elevated amyloid β protein (Aβ42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet. 2005;14(3):447–460
  17. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. A meta-analysis. JAMA. 1997;278:1349–1356
  18. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 2003;100(7):4162–4167
  19. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol. 2004;164(4):1425–1434
  20. Folstein MF, Folstein SE, McHugh PR. ’Mini Mental State’. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–198
  21. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356
  22. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001;29(3):306–309
  23. Kehoe P, Vrieze FW-D, Crook R, Wu W, Holmans P, Fenton I, et al. A full genome scan for late onset Alzheimer's disease. Hum Mol Genet. 1999;8:237–245
  24. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40(6):1087–1093
  25. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33(2):177–182
  26. McKhann G, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  27. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA. 2003;100(10):6221–6226
  28. Mueller JC, Lohmussaar E, Magi R, Remm M, Bettecken T, Lichtner P, et al. Linkage disequilibrium patterns and tagSNP transferability among European populations. Am J Hum Genet. 2005;76(3):387–398
  29. Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JP, Pyrek JS, Estus S, et al. Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci. 2000;20(23):8745–8749
  30. Myers A, De-Vrieze FW, Holmans P, Hamshere M, Crook R, Compton D, et al. Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet. 2002;114:235–244
  31. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science. 2000;290:2304–2305
  32. Neale BM, Sham PC. The future of association studies: gene-based analysis and replication. Am J Hum Genet. 2004;75(3):353–362
  33. Nowotny P, Hinrichs AL, Smemo S, Kauwe JS, Maxwell T, Holmans P, et al. Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am J Med Genet B Neuropsychiat Genet. 2005;
  34. Pericak-Vance M, Bass M, Yamaoka L, Gaskell P, Scott W, Terwedow H, et al. Complete genomic screen in late onset Alzheimer's disease. JAMA. 1997;278:1237–1241
  35. Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K, et al. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat. 2003;22(5):363–371
  36. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet. 2002;71(5):1242–1247
  37. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273(49):32730–32738
  38. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, et al. CAMDEX. A standardized instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiat. 1986;149:698–709
  39. Sakai A, Ujike H, Nakata K, Takehisa Y, Imamura T, Uchida N, et al. No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population. Am J Med Genet B Neuropsychiat Genet. 2004;125(1):87–91
  40. Saunders AM, Schmader K, Breitner JCS, Benson MD, Brown WT, Goldfarb L, et al. Apolipoprotin E e4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 1993;(342):710–711
  41. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000;20(5):1657–1665
  42. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994;44:609–614
  43. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered. 2002;53(2):79–91
  44. Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem. 1997;43:1657–1659

PII: S0197-4580(06)00106-0

doi: 10.1016/j.neurobiolaging.2006.03.009

Neurobiology of Aging
Volume 28, Issue 5 , Pages 727-734 , May 2007

Article Tools

* Image Usage & Resolution